Boston Scientific Co. (NYSE:BSX) EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $43.33, for a total value of $216,650.00. Following the transaction, the executive vice president now directly owns 29,201 shares in the company, valued at $1,265,279.33. The sale was disclosed in a filing with the SEC, which is available through this link.
Boston Scientific stock opened at $42.61 on Wednesday. The stock has a 50-day moving average price of $41.18 and a 200 day moving average price of $41.31. The company has a market capitalization of $60.28 billion, a price-to-earnings ratio of 28.99, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. Boston Scientific Co. has a 52 week low of $31.56 and a 52 week high of $43.84. The company has a quick ratio of 0.77, a current ratio of 1.14 and a debt-to-equity ratio of 0.99.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.01. Boston Scientific had a net margin of 10.49% and a return on equity of 23.10%. The company had revenue of $2.71 billion for the quarter, compared to the consensus estimate of $2.68 billion. During the same quarter in the prior year, the company earned $0.35 EPS. Boston Scientific’s quarterly revenue was up 13.1% on a year-over-year basis. Research analysts anticipate that Boston Scientific Co. will post 1.57 EPS for the current fiscal year.
BSX has been the subject of several recent analyst reports. Raymond James lowered their price target on Boston Scientific from $50.00 to $48.00 and set a “strong-buy” rating for the company in a report on Monday, October 14th. Barclays reaffirmed an “overweight” rating and issued a $48.00 price objective on shares of Boston Scientific in a research report on Tuesday, September 3rd. Stephens set a $48.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Monday, September 30th. ValuEngine downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. Finally, Needham & Company LLC restated a “buy” rating and set a $53.00 price target on shares of Boston Scientific in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $47.19.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.